---
layout: default
title: Aluminum Oxide Bryonia Alba Root Graphite Lead Lyc
parent: 僅模型預測 (L5)
nav_order: 296
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Bryonia Alba Root Graphite Lead Lyc
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Combination: Repurposing Evaluation Not Feasible

## One-Sentence Summary

This Evidence Pack describes a twelve-ingredient homeopathic polypharmacy product (containing Bryonia Alba Root, Lycopodium Clavatum Spore, Strychnos Nux-Vomica Seed, Sepia Officinalis Juice, Sulfur, and seven additional mineral/botanical substances), which holds no marketing authorization in Taiwan and has no DrugBank ID on record. The TxGNN model generated **no predicted indications** for this compound, and no original approved indication could be retrieved from any queried source. Because the minimum data required to conduct a repurposing evaluation is absent, this submission cannot proceed through the standard pipeline at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction absent — evaluation not initiated) |
| Market Status | Not marketed (Taiwan TFDA: 0 authorizations) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predictions are available for this compound, so a standard mechanistic rationale cannot be constructed. The submitted entity is a twelve-ingredient homeopathic combination comprising botanical extracts (Bryonia Alba Root, Lycopodium Clavatum Spore, Matricaria Recutita, Sepia Officinalis Juice, Strychnos Nux-Vomica Seed), elemental sulfur, and a set of mineral substances (Aluminum Oxide, Graphite, Lead, Magnesium Chloride, Silicon Dioxide, Sodium Chloride). Homeopathic polypharmacy products of this type are not easily mapped to a single DrugBank entry or a unified INN, which most likely explains the absent DrugBank ID and the failure of the prediction pipeline to return candidates.

Detailed mechanism of action data is not available. Because the compound lacks a linked DrugBank ID and no original approved indication has been documented, the TxGNN knowledge graph was unable to establish sufficient node-to-node relationships to generate repurposing candidates. The query log confirms that the TFDA search returned zero records and the DDI database similarly returned no matches, though the DrugBank query did return one result — suggesting partial data exists that may be exploitable if individual ingredients are queried separately.

Without a defined original indication and without TxGNN output, there is no mechanistic or epidemiological bridge to evaluate. A repurposing assessment can only proceed after the critical data gaps identified below are resolved.

---

## Market Authorization Status

This product currently holds **no marketing authorization** in Taiwan (TFDA). No NDA, license number, dosage form, or approved indication text is on record. The product is classified as **未上市** (not marketed).

---

## Safety Considerations

Please refer to the package insert for safety information.

Additionally, one ingredient warrants proactive attention regardless of dilution level: **Lead (Pb)** is a known neurotoxic heavy metal. Even in homeopathic preparations, any finished product containing a lead-derived substance should be assessed against current regulatory guidelines on permissible heavy metal limits (e.g., ICH Q3D, USP <232>) before any clinical use or repurposing study is considered.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack lacks a DrugBank ID, an approved original indication, TxGNN predicted indications, and all safety data — the four pillars necessary for even a preliminary repurposing evaluation. Proceeding without these would produce unreliable conclusions.

**To proceed, the following is needed:**

- **Resolve ingredient-level DrugBank mapping**: Query individual active substances (e.g., Bryonia Alba, Nux Vomica Seed, Sulfur, Sepia Officinalis) separately; if any return valid DrugBank IDs, re-run the TxGNN pipeline on those individual components
- **Confirm product identity and regulatory status**: Determine whether this is a registered homeopathic OTC product (possibly in other jurisdictions) or a wholly unapproved compound; retrieve any available package insert
- **Document the original therapeutic claim**: Even homeopathic products carry labelled claims; identifying the claimed indication is necessary to frame the "From → To" repurposing hypothesis
- **Re-run TxGNN prediction**: Once at least one ingredient has a confirmed DrugBank ID and disease association, restart the prediction pipeline
- **Heavy metal safety assessment**: Conduct a Lead (Pb) content and dilution analysis against ICH Q3D Parenteral/Oral limits before any clinical pathway is considered
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

